최근 시세가 확인되지 않는 종목 최근 5거래일간 시세가 수집되지 않았습니다. 거래 정지·상장 폐지 여부를 확인 중입니다.
GLTO
Damora Therapeutics Inc
$28.69
-0.22 ▼ -0.76%
다모라 테라퓨틱스(GLTO) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$1.7B
스몰캡
P/E
-
배당수익률
없음
52주 위치
73%
저점 +1327% · 고점 -25%
애널리스트
적극 매수
B
Fundamental health
vs. 전체 시장· based on 2 axes
수익성 산출 불가 (적자)
성장 Top 36%
밸류에이션 데이터 부족
재무 안정 Top 37%
| Index | - | P/E | - | EPS (ttm) | -12.1 | Insider Own | 7.63% | Shs Outstand | 60.2M | Perf Week | -4.53% |
| Market Cap | 1.73B | Forward P/E | - | EPS next Y | -11.96% | Insider Trans | -0.02% | Shs Float | 55.6M | Perf Month | 26.78% |
| Enterprise Value | 1.72B | PEG | - | EPS next Q | -0.11 | Inst Own | 16.1% | Short Float | 0.5% | Perf Quarter | 25.34% |
| Income | -0.02B | P/S | - | EPS this Y | 94.84% | Inst Trans | 1.75% | Short Ratio | 1.56 | Perf Half Y | 853.16% |
| Sales | 0.00B | P/B | 5.71 | EPS next 5Y | 56.9% | ROA | -92.89% | Short Interest | 0.28M | Perf YTD | 24.68% |
| Book/sh | 5.02 | P/C | 227.11 | EPS past 3/5Y | 28.75% 14.83% | ROE | -114.81% | 52W High | -25.14% ($38.33) | Perf Year | 606.65% |
| Cash/sh | 0.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | -196.48% | 52W Low | 1327.36% ($2.01) | Perf 3Y | -40.23% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.42% | Gross Margin | - | Volatility(W/M) | 9.28% 11.03% | Perf 5Y | -88.51% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.86 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.73 | EPS Q/Q | 30.38% | Profit Margin | - | RSI (14) | 51.68 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.73 | Sales Q/Q | - | SMA20 | -0.09% ($28.72) | Beta | 1.57 | Target Price | $46.75 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 2025/11/6 | SMA50 | 8.59% ($26.42) | Rel Volume | 1.31 | Prev Close | $28.91 |
| Employees | 5 | LT Debt/Eq | 0.21 | EPS/Sales Surpr. | - | SMA200 | 120.73% ($13) | Avg Volume(3M) | 0.18M | Price | $28.69 |
| IPO | 2020/10/29 | Option/Short | No/Yes | Trades | 4132 | Volume | 231,433 | Change | -0.76% |
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.
Damora Therapeutics Inc (GLTO) Investment Analysis
What kind of company is Damora Therapeutics Inc?
다모라 테라퓨틱스(GLTO)
Healthcare · Biotechnology
Healthcare Stocks
🧬 This is a US clinical-stage biotech company developing blood cancer therapies. It is developing antibody therapeutics targeting blood disorders such as myeloproliferative neoplasms caused by specific gene mutations, and holds a leading early-clinical-stage candidate along with a well-funded balance sheet. Formerly known as Galecto, it has rebranded as a blood cancer antibody biotech, and its stock performance is heavily dependent on clinical progress.
Learn more about Damora Therapeutics Inc →Market Cap
$1.7B
Approx. KRW 2.4 trillion
⚖️ 1% of Samsung Electronics
Market Cap Rank2133
Employees5people
IPO2020/10/29
Current Price$28.69 ≈ 39,305원
Key Events
예정된 이벤트가 없습니다
GLTO의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.
- 실적 발표는 보통 분기마다 있습니다
- 배당주는 연 1~4회 배당락일이 있습니다
Is it profitable?
Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-114.8%
✓ 적자
ROA
Annual earnings relative to total company assets
-92.9%
✓ 적자
ROIC
Return generated per dollar invested in the business
-196.5%
✓ 적자
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.21
✓ Healthy debt
Current Ratio
Liquid assets available to cover liabilities due within a year
3.73
✓ 우수
Quick Ratio
Liquid assets excluding inventory, available for immediate use
3.73
✓ 우수
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$46.75
현재가 대비 +62.9%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
-12.0%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+56.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
Insufficient historical earnings data
No analyzable past earnings releases have been collected yet.
Is it growing?
Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+94.8%
우수
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-12.0%
매우 부진
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+56.9%
우수
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+28.8%
양호
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+14.8%
양호
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Long-term weakness — -157%p below the market
GLTO -88.5% · S&P 500 +68.4%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-156.9%p
Significantly behind the market
vs Health Care (XLV)
-113.0%p
Significantly behind the sector average
1-year basis
vs S&P 500
+590.6%p
well ahead of the market
vs Health Care (XLV)
+586.9%p
well ahead of the sector average
Current position within 52-week range
Low (-1327.4%p) High (-25.1%p)
Current price is 1327.4% above the 52-week low and 25.1% below the 52-week high
Recent risk (last 32 trading days)
Max drawdown
-21.3%
Annualized volatility
120.1%
Is it attractive at this price?
Pricier than peers in its industry
Pricey on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Assets Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
5.71x
✓ Pricey
Analyst target price (reference)
$46.75 vs. current price +62.9%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: 전체 시장
Who owns it?
Ownership flow is positive
Insider modest net selling -0.0% · Institutional net buying +1.8% · Short interest light 0.5% · Short interest fell -15.9%p over the last 32 days
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-0.0%
Insiders little change
🏦 Institutions (funds & investors)
+1.8%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 16.1%
Retail-led
🧑💼 Insiders 7.6%
Meaningful insider stake
👤 Retail investors (estimated) 76.3%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
0.5%
Low — limited short-side pressure
Past 32 days 📉 -15.9%p decrease
Short interest days to cover
1.6 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 60.2M주
Float (tradable shares) 55.6M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 32 days.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| GLTO This Stock | $1.7B | - | 5.7 ▼ | -114.81% ▼ | - | -0.8% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 다모라 테라퓨틱스(GLTO)?
다모라 테라퓨틱스(GLTO) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GLTO?
The market cap of GLTO is approximately $1.7B, ranking 2,133 within its sector.
What is the 52-week high and low for GLTO?
GLTO has recorded a 52-week high of $38.33 and a low of $2.01.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.